Sleep disorder in patients with metastatic cancer.
Conditions
Interventions
Intervention 1: Intervention group: Mirtazapine 15 to 30 mg orally is used on days 1 to 4 after chemotherapy. Intervention 2: Intervention group: Lorazepam 1 to 2 mg is used on days 1 to 4 after chemo
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with various types of cancer undergoing chemotherapy who are suffering from insomnia at the beginning of the study based on the interview and initial examination of the psychiatrist (relevant assistant and professor). Patients should not be suffering from other psychiatric disorders or have previously been involved and treated with the investigated disorders. Patients should not be under the influence of drugs and alcohol. The age range of patients is between 15 and 65 years. Patients must be able to communicate with the doctor during the 6 weeks of the study.
Exclusion criteria
Exclusion criteria: Inability to fill out questionnaires People who score higher than the detection limit according to the HADS questionnaire are excluded from the study. Suffering from chronic physical diseases except cancer Suffering from other psychiatric diagnoses Use of various substances and alcohol during the past month. Previous drug sensitivity to mirtazapine and yalorazepam. Lack of consent of the patient or guardian to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improving sleep quality questionnaire scores. Timepoint: Initial interview, three days later and six weeks later. Method of measurement: Petersburg Sleep Questionnaire and HADS. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKiana Kouti
Shahid Beheshti University of Medical Sciences
Outcome results
None listed